Nitrobenzylthioinosine binding in brain: an interspecies study.
The binding of the potent adenosine uptake inhibitor [3H]nitrobenzylthioinosine ( [3H]NBI) to cerebral cortical membrane preparations from human, dog, guinea pig, rat, and mouse was investigated. Reversible, specific, saturable, high affinity binding was found in all five species with similar kinetic parameters. (Kd = 0.16-0.44 nM; Bmax = 128-196 fmol/mg prot.). Dilazep, hexobendine, and dipyridamole were all high potency inhibitors of [3H]NBI binding in human, dog, guinea pig and mouse preparations but not in rat. These compounds showed a competitive inhibition of [3H]NBI binding indicating that they are acting at the same site. Discrepancies seen in the rat appear to be a unique, species related anomaly. The dihydropyridine calcium antagonists also inhibited binding with lower potency than the adenosine uptake blockers. This inhibition was most potent in dog and human and suggests a relationship between the calcium channel and the adenosine uptake site.
D000818:Animals; D001921:Brain / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002540:Cerebral Cortex / Q000378:metabolism; D004095:Dihydropyridines; D004285:Dogs; D006168:Guinea Pigs; D006801:Humans; D007288:Inosine / Q000031:analogs & derivatives*; D007700:Kinetics; D051379:Mice; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013045:Species Specificity; D013868:Thioinosine / Q000031:analogs & derivatives* / Q000378:metabolism
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D011725:Pyridines; D013868:Thioinosine; D007288:Inosine; C038806:1,4-dihydropyridine; C001789:4-nitrobenzylthioinosine